ALFA Filings
Every announcement, straight from the exchange
Every Jagsonpal Pharmaceuticals merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
9 announcements with these filters
Jagsonpal Pharmaceuticals has completed the acquisition of an 85% equity stake in Aequitas Healthcare. This follows initial acquisition intimations made in June 2026.
Jagsonpal Pharmaceuticals completed the acquisition of a 69.77% stake in Aequitas Healthcare, turning it into a subsidiary. No monetary value was disclosed.
Jagsonpal Pharmaceuticals is acquiring an 85% stake in Aequitas Healthcare for ₹20.78 Crore. This strategic move provides access to hospital channels and institutional doctor networks.
Jagsonpal Pharmaceuticals will acquire an 85% stake in Aequitas Healthcare for ₹20.8 Crore. The transaction marks its strategic entry into the hospital segment.
Jagsonpal Pharmaceuticals extinguished 16,00,000 equity shares following a successful buyback via tender offer. The post-buyback paid-up capital now stands at Rs. 13.11 Crore.
Jagsonpal Pharmaceuticals completed a ₹40 Crore equity share buyback via the tender offer route. The company repurchased 1,600,000 shares, increasing promoter holding to 69.36%.
Jagsonpal Pharmaceuticals Ltd announced a share buyback of 16,00,000 equity shares via a tender offer at ₹250 per share. The total buyback size is capped at ₹40 Crore. The offer opens on May 8, 2026, and closes on May 14, 2026, aimed at returning capital to shareholders.
Jagsonpal Pharmaceuticals Limited announced a buyback of up to 16,00,000 equity shares at ₹250 per share, totalling ₹40 Crore. The buyback, representing 2.38% of paid-up capital, opens on May 08, 2026, and closes on May 14, 2026.
Jagsonpal Pharmaceuticals Limited announced a buyback of up to 16,00,000 equity shares at ₹250 per share, totaling ₹40 Crore. The buyback will be conducted via a tender offer on a proportionate basis. The company has fixed May 4, 2026, as the record date to determine eligible shareholders for the offer.